Clarity For Celgene On Revlimid, A Backbone Of MM Treatment

Celgene reached a patent settlement with generic rival Natco that will allow entry of generic lenalidomide in March 2022, but only a limited quantity initially.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet